Research Article
Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy
Figure 2
(a) CD4+/CD38+/DR+, (b) CD8+/CD38+/DR+, percentage of apoptotic T cells, (c) CD4+/CD95+, (d) CD8+/CD95+. Line represents median; rank-sum test; BL: baseline.